In a European study of people newly diagnosed with multiple sclerosis (MS), B-cell-depleting treatments were linked to fewer relapses and greater reductions in brain lesion volume over two years compared with oral treatments. However, changes in disability scores were similar across treatment groups.
Discussion
Physical activity programs led by healthcare professionals appear acceptable and feasible for adults with multiple sclerosis (MS), a review found. However, more research is needed to determine whether these programs can be successfully used in everyday clinical care. The findings were published in the study, “The implementability of…
Discussion
Most people with relapsing or progressive forms of multiple sclerosis (MS) had stable or improved disability scores, along with signs of reduced disease activity, after receiving a single infusion of the experimental CAR T-cell therapy zolacabtagene autoleucel (zola-cel). That’s according to interim results from a Phase 1 clinical trial,…
Discussion
Fewer people with multiple sclerosis (MS) are willing to receive recommended routine vaccines today than before the COVID-19 pandemic, even as neurologists and family doctors talk with them more frequently about immunization, a new study in Germany has found. While vaccination records showed improved coverage for several vaccines, researchers…
Discussion
Most people with progressive forms of multiple sclerosis (MS) had stable or improved disability scores after receiving the experimental CAR T-cell therapy azercabtagene zapreleucel (azer-cel)Â in a small Phase 1 clinical trial. TG Therapeutics, which is developing azer-cel under a licensing agreement with its previous developer, Precision…
Get regular updates to your inbox.
